Secor Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Secor Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-27,767	Closed	-$371K	–	437
2018 Q4	$371K	Buy	+27,767	New	+$367K	0.05%	345
2018 Q2	–	Sell	-40,985	Closed	-$674K	–	521
2018 Q1	$674K	Buy	+40,985	New	+$759K	0.06%	344
2017 Q3	–	Sell	-36,689	Closed	-$433K	–	449
2017 Q2	$433K	Buy	+36,689	New	+$399K	0.04%	361
2017 Q1	–	Sell	-14,784	Closed	-$107K	–	484
2016 Q4	$107K	Buy	+14,784	New	+$116K	0.01%	477

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Secor Capital Advisors's CORT Position: Q1 2019 in Review

Secor Capital Advisors sold out of Corcept Therapeutics (CORT) in Q1 2019, closing a stake of 27,767 shares — an estimated $371K sold.

Secor Capital Advisors first reported a position in CORT in Q4 2016 and held it in 4 quarters. The position peaked at $674K in Q1 2018. 208 funds tracked by Wall St. Rank hold CORT as of Q1 2019.

Secor Capital Advisors reported no remaining Corcept Therapeutics position as of Q1 2019 after selling out during the quarter.
Secor Capital Advisors sold 27,767 Corcept Therapeutics shares in Q1 2019, an estimated $371K.
Secor Capital Advisors first reported a position in Corcept Therapeutics in Q4 2016 and held it in 4 quarters.
Secor Capital Advisors's Corcept Therapeutics position peaked at $674K in Q1 2018.
208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.